BR0107942A - Polìmeros de proteìna de liberação lenta - Google Patents

Polìmeros de proteìna de liberação lenta

Info

Publication number
BR0107942A
BR0107942A BR0107942-5A BR0107942A BR0107942A BR 0107942 A BR0107942 A BR 0107942A BR 0107942 A BR0107942 A BR 0107942A BR 0107942 A BR0107942 A BR 0107942A
Authority
BR
Brazil
Prior art keywords
slow release
protein polymers
release protein
articles
methods
Prior art date
Application number
BR0107942-5A
Other languages
English (en)
Inventor
Stephen C Rowe
Kalvin Yim
Beadle P Retnarajan
Jeffrey A Hubbell
Durga Annavajula
Original Assignee
Infimed Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infimed Therapeutics Inc filed Critical Infimed Therapeutics Inc
Publication of BR0107942A publication Critical patent/BR0107942A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Abstract

"POLìMEROS DE PROTEìNA DE LIBERAçãO LENTA". A invenção caracteriza artigos para distribuição de uma substância biologicamente ativa, métodos para produzir tais artigos, e métodos para tratar uma animal usando os artigos.
BR0107942-5A 2000-01-28 2001-01-29 Polìmeros de proteìna de liberação lenta BR0107942A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17885200P 2000-01-28 2000-01-28
PCT/US2001/002828 WO2001055360A1 (en) 2000-01-28 2001-01-29 Slow release protein polymers

Publications (1)

Publication Number Publication Date
BR0107942A true BR0107942A (pt) 2004-01-06

Family

ID=22654167

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0107942-5A BR0107942A (pt) 2000-01-28 2001-01-29 Polìmeros de proteìna de liberação lenta

Country Status (10)

Country Link
US (3) US6699504B2 (pt)
EP (1) EP1255823A4 (pt)
JP (1) JP2003520810A (pt)
KR (1) KR20030009346A (pt)
CN (1) CN1606620A (pt)
AU (1) AU785288B2 (pt)
BR (1) BR0107942A (pt)
CA (1) CA2398788A1 (pt)
MX (1) MXPA02007281A (pt)
WO (1) WO2001055360A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520810A (ja) * 2000-01-28 2003-07-08 インファイムド セラピューティクス インコーポレイテッド 徐放性タンパク質ポリマー
US6652883B2 (en) 2000-03-13 2003-11-25 Biocure, Inc. Tissue bulking and coating compositions
US6676971B2 (en) 2000-03-13 2004-01-13 Biocure, Inc. Embolic compositions
JP5460939B2 (ja) 2000-03-13 2014-04-02 バイオコンパティブルズ ユーケー リミテッド ヒドロゲル生物医学用製品
EP1406946B1 (en) * 2001-07-14 2007-06-20 Samyang Corporation Positively charged amphiphilic block copolymer as drug carrier and complex thereof with negatively charged drug
EP1469893A1 (de) * 2002-02-01 2004-10-27 Sustech GmbH & Co. KG Sternformige prapolymere fur die herstellung ultradunner hydrogel-bildender beschichtungen
AU2003221497A1 (en) * 2002-03-13 2003-09-22 Novartis Ag Pharmaceutical microparticles
FR2854072B1 (fr) * 2003-04-23 2006-08-04 Centre Nat Rech Scient Vecteur pour administration par voie orale
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
WO2005040195A2 (en) * 2003-10-24 2005-05-06 Azopax Therapeutics Llc Formulation of exendins
WO2005072764A2 (en) * 2004-01-16 2005-08-11 Novocell, Inc. Fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
US7931693B2 (en) * 2004-02-26 2011-04-26 Endosphere, Inc. Method and apparatus for reducing obesity
US8147561B2 (en) 2004-02-26 2012-04-03 Endosphere, Inc. Methods and devices to curb appetite and/or reduce food intake
US8585771B2 (en) 2004-02-26 2013-11-19 Endosphere, Inc. Methods and devices to curb appetite and/or to reduce food intake
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
US8128952B2 (en) * 2005-01-12 2012-03-06 Clemson University Research Foundation Ligand-mediated controlled drug delivery
EP1838305A1 (en) * 2005-01-21 2007-10-03 Richard H. Matthews Radiosensitizer formulations comprising nitrohistidine derivatives
DE102005017777A1 (de) * 2005-04-13 2006-10-19 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Partikelsuspensionen
CA2604770C (en) * 2005-04-13 2013-09-24 Abbott Gmbh & Co. Kg Method for carefully producing ultrafine particle suspensions and ultrafine particles and use thereof
US8263103B2 (en) * 2006-01-31 2012-09-11 Boston Scientific Scimed, Inc. Medical articles containing biodegradable polymers and acid-neutralizing cationic species
DE102006009004A1 (de) * 2006-02-23 2007-09-06 Sustech Gmbh & Co. Kg Multifunktionelle sternförmige Präpolymere, deren Herstellung und Verwendung
US9060835B2 (en) 2006-05-26 2015-06-23 Endosphere, Inc. Conformationally-stabilized intraluminal device for medical applications
US8071544B2 (en) * 2006-12-18 2011-12-06 Althea Technologies, Inc. Crystallized recombinant human growth factor formulations
EP1961411A1 (en) * 2007-02-21 2008-08-27 FUJIFILM Manufacturing Europe B.V. A controlled release composition
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
TR200704897A1 (tr) * 2007-07-13 2009-02-23 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Uzatılmış salım sağlayan gliklazid formülasyonları@
US20110137227A1 (en) 2007-07-16 2011-06-09 Mckinley James T Methods and devices for delivering or delaying lipids within a duodenum
DE102007045097B4 (de) * 2007-09-20 2012-11-29 Heraeus Quarzglas Gmbh & Co. Kg Verfahren zur Herstellung von co-dotiertem Quarzglas
JP5738291B2 (ja) 2009-07-31 2015-06-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリンリンカー複合体を含むプロドラッグ
JP5732053B2 (ja) 2009-07-31 2015-06-10 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 持続型インスリン組成物
US20120180785A1 (en) * 2009-09-29 2012-07-19 Helen Mary Trill Pressurized Metered Dose Inhalers
CN106913902A (zh) 2009-11-09 2017-07-04 聚光灯技术合伙有限责任公司 多糖基水凝胶
EP2498764B1 (en) 2009-11-09 2017-09-06 Spotlight Technology Partners LLC Fragmented hydrogels
WO2011068903A1 (en) * 2009-12-01 2011-06-09 Baylor College Of Medicine Methods and compositions for bone formation
US8865220B2 (en) * 2010-06-14 2014-10-21 Kaohsiung Medical University Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres
US9232805B2 (en) 2010-06-29 2016-01-12 Biocure, Inc. In-situ forming hydrogel wound dressings containing antimicrobial agents
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
WO2012050359A2 (ko) * 2010-10-14 2012-04-19 (주)아모레퍼시픽 리피드로 코팅된 하이드로겔 입자 및 이의 제조방법
CN102731791B (zh) * 2011-04-13 2016-04-13 北京大学 温度敏感型嵌段共聚物及其水凝胶和其用途
CN103976982A (zh) * 2014-06-03 2014-08-13 长春理工大学 一种包载重组人生长激素缓释药物微囊
US10004753B2 (en) 2015-01-16 2018-06-26 The J. David Gladstone Institutes Methods for treating tauopathy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
ATE197125T1 (de) * 1992-02-28 2000-11-15 Univ Texas Photopolymerinierbare, biologisch abbaubare hydrogele als gewebekontaktmaterialien und trägerstoffe für kontrollierte freisetzung
DE69520044T2 (de) * 1994-10-12 2001-06-13 Focal Inc Zielgerichte verabreichung mittels biologisch abbaubarer polymere
IL134084A0 (en) * 1997-07-18 2001-04-30 Infimed Inc Biodegradable macromers for the controlled release of biologically active substances
EP1512395A1 (en) * 1997-07-18 2005-03-09 Azopax Therapeutics LLC Biodegradable macromers for the controlled release of biologically active substances
US6007833A (en) 1998-03-19 1999-12-28 Surmodics, Inc. Crosslinkable macromers bearing initiator groups
JP2003520810A (ja) * 2000-01-28 2003-07-08 インファイムド セラピューティクス インコーポレイテッド 徐放性タンパク質ポリマー

Also Published As

Publication number Publication date
US20060003009A1 (en) 2006-01-05
AU785288B2 (en) 2006-12-21
AU2978201A (en) 2001-08-07
KR20030009346A (ko) 2003-01-29
CN1606620A (zh) 2005-04-13
EP1255823A4 (en) 2007-10-31
CA2398788A1 (en) 2001-08-02
US6939557B2 (en) 2005-09-06
US20010048947A1 (en) 2001-12-06
WO2001055360A1 (en) 2001-08-02
US6699504B2 (en) 2004-03-02
MXPA02007281A (es) 2002-12-09
EP1255823A1 (en) 2002-11-13
US20040156914A1 (en) 2004-08-12
JP2003520810A (ja) 2003-07-08

Similar Documents

Publication Publication Date Title
BR0107942A (pt) Polìmeros de proteìna de liberação lenta
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
CY1112458T1 (el) Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
BR0202519B1 (pt) métodos para tratamento de material de madeira e para tratamento microbicida de material de madeira.
AR016981A2 (es) Polipeptidos sinteticos
DE59902006D1 (de) Wirkstoffhaltige aromatische copolyester
ITBO970563A0 (it) Macchina operatrice, e relativo procedimento, per la lavorazione di corpi piani.
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
BR9712904A (pt) Agentes de tratamento de plantas
PT1044064E (pt) Dispositivo para o revestimento de granulos destinados a serem absorvidos por via oral
CY1105463T1 (el) Ελεγχομενη χορηγηση αντικαταθλιπτικων
BR7902303Y1 (pt) tambor para tratamento de couros, peles e similares.
ES2179908T3 (es) Acidos sacarosamonocarboxilicos acilados.
DE29818305U1 (de) Einrichtung zur Behandlung von Tieren, insbesondere Pferden
DE29505177U1 (de) Vorrichtung zur künstlichen Befruchtung von Tieren, insbesondere Sauen
IT1318509B1 (it) Polimeri reticolati, utili per uso farmaceutico, medicale e cosmetico.
IT1301684B1 (it) Acilperossidi perfluoropolieterei e procedimento per il loroottenimento.
PT1150716E (pt) Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao
ITBO970367A0 (it) Macchina operatrice, e relativo procediemento, per la lavorazione di corpi piani.
ES1038880Y (es) Soporte de envase para inseminacion artificial de ganado porcino.
ES1036955Y (es) Dispositivo para la captura de animales.
ES1043194Y (es) Comedero para la 1 edad de animales estabulados.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A, 10A E 11A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.